In light of coronavirus crisis, resilience is crucial, says Takeda GM

Arie Kramer spoke to 'The Jerusalem Post' about the role of Big Pharma in a health crisis, the importance of meriting people’s trust and what they are doing to help.

A researcher at the University of Pittsburgh works on a COVID-19 vaccine candidate, a fingertip-size
Moderna, Pfizer start pivotal COVID-19 vaccine trials, eye year-end launch

The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by COVID-19.

Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe
Pfizer, BioNTech say vaccine expected to be ready for approval by December

If it receives marketing approval, the companies are preparing to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021.

Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe
BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

"These first trial results show that the vaccine yields immune activity and causes a strong immune response," said BioNTech's co-founder and Chief Executive Officer Ugur Sahin.

Bayer to test new drugs on 3D-printed heart tissue at Tel Aviv University

The new method of testing bypasses many tedious screening methods, making it faster, cheaper and more efficient.

Canadian company Medicago develops plant-based coronavirus vaccine

The company has developed a unique method of creating a vaccine by letting plants do the work. "We're using plants as mini factories," said Natalie Charland, a senior director at Medicago.

Hillel's Tech Corner: CytoReason: Where AI meets drug development

CytoReason’s technology uses a machine learning model to build a molecular level understanding of tissues in diseases on the cellular level.

The Lounge March 10, 2020: SuperPharm

A number of Super Pharm’s managers attended the ceremony, and Kupler and Keshet arranged to meet again in the future to discuss continued cooperation.

Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020
After turbulent years, Teva CEO Schultz forecasts stability

Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.

Professor Ruth Arnon, who was awarded the 2020 OurCrowd Maimonides Award for Lifetime Achievement in
86-year-old Copaxone creator has no intention of slowing down

When it comes to being excited by experiments, age is simply not a factor for 86-year-old Prof. Ruth Arnon, co-creator of multiple sclerosis drug Copaxone.

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use